Last reviewed · How we verify

Moroctocog alfa (AF-CC)

Pfizer · FDA-approved active Biologic

Moroctocog alfa (AF-CC) is a Recombinant coagulation factor VIII Biologic drug developed by Pfizer. It is currently FDA-approved for Hemophilia A (congenital factor VIII deficiency) for treatment and prevention of bleeding episodes. Also known as: Xyntha, ReFacto AF.

Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.

Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients. Used for Hemophilia A (congenital factor VIII deficiency) — treatment and prophylaxis of bleeding episodes.

At a glance

Generic nameMoroctocog alfa (AF-CC)
Also known asXyntha, ReFacto AF
SponsorPfizer
Drug classRecombinant coagulation factor VIII
TargetCoagulation factor VIII
ModalityBiologic
Therapeutic areaHematology
PhaseFDA-approved

Mechanism of action

Factor VIII is a critical cofactor in the intrinsic coagulation cascade that works with von Willebrand factor to activate factor X, ultimately leading to thrombin generation and fibrin clot formation. Moroctocog alfa (AF-CC) is a B-domain deleted recombinant factor VIII with an added albumin fusion domain to extend half-life. By providing functional factor VIII, it corrects the coagulation defect in hemophilia A, enabling normal hemostasis and reducing bleeding episodes.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Moroctocog alfa (AF-CC)

What is Moroctocog alfa (AF-CC)?

Moroctocog alfa (AF-CC) is a Recombinant coagulation factor VIII drug developed by Pfizer, indicated for Hemophilia A (congenital factor VIII deficiency) for treatment and prevention of bleeding episodes.

How does Moroctocog alfa (AF-CC) work?

Moroctocog alfa is a recombinant human coagulation factor VIII that replaces deficient or dysfunctional factor VIII to restore blood clotting ability in hemophilia A patients.

What is Moroctocog alfa (AF-CC) used for?

Moroctocog alfa (AF-CC) is indicated for Hemophilia A (congenital factor VIII deficiency) for treatment and prevention of bleeding episodes.

Who makes Moroctocog alfa (AF-CC)?

Moroctocog alfa (AF-CC) is developed and marketed by Pfizer (see full Pfizer pipeline at /company/pfizer).

Is Moroctocog alfa (AF-CC) also known as anything else?

Moroctocog alfa (AF-CC) is also known as Xyntha, ReFacto AF.

What drug class is Moroctocog alfa (AF-CC) in?

Moroctocog alfa (AF-CC) belongs to the Recombinant coagulation factor VIII class. See all Recombinant coagulation factor VIII drugs at /class/recombinant-coagulation-factor-viii.

What development phase is Moroctocog alfa (AF-CC) in?

Moroctocog alfa (AF-CC) is FDA-approved (marketed).

What are the side effects of Moroctocog alfa (AF-CC)?

Common side effects of Moroctocog alfa (AF-CC) include Inhibitor development (factor VIII antibodies), Injection site reactions, Headache, Hypersensitivity reactions.

What does Moroctocog alfa (AF-CC) target?

Moroctocog alfa (AF-CC) targets Coagulation factor VIII and is a Recombinant coagulation factor VIII.

Related